KBI Biopharma

KBI Biopharma is a well-established, global CDMO specializing in biologics, with a strong focus on mammalian and microbial expression systems. Founded in 1996, it operates facilities in the US (Durham, NC) and Switzerland (Geneva), offering integrated services from early development through commercial supply. The company positions itself as a 'next-generation CDMO,' leveraging proprietary technology platforms like the KBI SUREtechnology Platform™ and KBI PUREplatform™ to deliver efficient, scalable, and high-quality manufacturing solutions for its biopharmaceutical clients.

KBI SUREtechnology Platform™ (mammalian CHO cell line development) and KBI PUREplatform™ (microbial E. coli expression).

KBI competes in a crowded global CDMO market against large players like Lonza, Catalent, and Samsung Biologics, as well as many mid-sized and specialized firms. It differentiates through its integrated mammalian and microbial platform technologies and a focus on flexible, single-use manufacturing for clinical and early commercial supply.